{
  "meta": {
    "title": "103_Covid_19_-_Treatment",
    "url": "https://brainandscalpel.vercel.app/103-covid-19-treatment-e0b6456f.html",
    "scrapedAt": "2025-11-30T12:28:22.437Z"
  },
  "questions": [
    {
      "text": "The airport authority sent a COVID-19 suspect patient to the designated district hospital for a consultation. He came positive on RT-PCR testing. As the duty doctor, you observe that he has mild symptoms that can be treated on an outpatient basis. What will be your recommendation?",
      "choices": [
        {
          "id": 1,
          "text": "Home isolation for 7 days from testing positive"
        },
        {
          "id": 2,
          "text": "Home quarantine for 10 days from testing positive"
        },
        {
          "id": 3,
          "text": "Home isolation for 10 days from testing positive"
        },
        {
          "id": 4,
          "text": "Home quarantine for 7 days from testing positive"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given scenario is a mild case of <strong>COVID-19</strong> who can be recommended <strong>home isolation</strong> for a duration of <strong>7&nbsp;days</strong>&nbsp;from testing positive.</p>\n<p><strong>Isolation</strong> is the separation and restriction of movements or activities of persons who are <strong>sick</strong>, to prevent the transmission of disease.</p>\n<p><strong>Eligibility for home isolation:</strong></p>\n<ul>\n<li>Clinically assigned as a mild or asymptomatic case&nbsp;</li>\n<li>Facility at their residence for self-isolation and for quarantining the family contacts</li>\n<li>Availability of a caregiver&nbsp;</li>\n<li>Must monitor his health regularly and inform his health status to the district surveillance officer</li>\n</ul>\n<p>The patient can <strong>end</strong> <strong>home isolation</strong> after <strong>7&nbsp;days from testing positive </strong>and<strong> no fever for 3 successive days.</strong>&nbsp;There is no need for testing after the home isolation period is over.</p>\n<p>The patient should <strong>seek medical help</strong> if he/she develops:</p>\n<ul>\n<li aria-level=\"1\">Unresolved High-grade fever (more than 100&deg; F for more than 3 days)</li>\n<li aria-level=\"1\">Difficulty in breathing,</li>\n<li aria-level=\"1\">Dip in oxygen saturation (SpO2 &le; 93% on room air at least 3 readings within 1 hour) or respiratory rate &gt;24/ min</li>\n<li aria-level=\"1\">Persistent pain/pressure in the chest</li>\n<li aria-level=\"1\">Mental confusion or inability to arouse</li>\n<li aria-level=\"1\">Severe fatigue and myalgia</li>\n</ul>\n<p><strong>Quarantine</strong> separates and restricts the movement of people who were <strong>exposed</strong> to a contagious disease to see if they become sick.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6823",
      "difficulty": "medium"
    },
    {
      "text": "A COVID-19 positive man is rushed to the casualty due to severe breathlessness. Examination findings are suggestive of pneumonia and his vitals are- PR: 90/min, BP: 134/88 mmHg, RR: 22/min and SpO2: 86%. What will you advise this patient?<div class='question-desc-html'><p>PR: 90/min</p>\n<p>BP: 134/88 mmHg</p>\n<p>RR: 22/min</p>\n<p>Temperature: 101 F</p>\n<p>SpO2: 86%</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Home isolation"
        },
        {
          "id": 2,
          "text": "Admit to COVID care center"
        },
        {
          "id": 3,
          "text": "Admit to ward"
        },
        {
          "id": 4,
          "text": "Admit to ICU"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The patient is suffering from <strong>severe COVID-19</strong> and hence has to be <strong>admitted to ICU.Â </strong>The disease is said to be severe when there is <strong>RR&gt;30/min</strong>, breathlessness OR <strong>SpO2&lt;90%</strong> on room air.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/fe5cb670ee104a838a63332770a2d0b0x1280x4371.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6832",
      "difficulty": "medium"
    },
    {
      "text": "A man presents with fever and cough for 2 days. His wife recently tested positive for COVID-19 and has been under home isolation. Examination findings are given below. What is not recommended in his management?<div class='question-desc-html'><p>Pulse- 110/min,</p>\n<p>BP- 78/58 mmHg,</p>\n<p>Temperature- 101.3 F</p>\n<p>RR- 28 cpm</p>\n<p>SpO2- 90% on room air</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Awake proning"
        },
        {
          "id": 2,
          "text": "Administration of paracetamol"
        },
        {
          "id": 3,
          "text": "Oxygen support"
        },
        {
          "id": 4,
          "text": "Prophylactic LMW heparin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div>\n<p class=\"p1\">The given clinical scenario is suggestive of&nbsp;<strong>moderate COVID-19 </strong>(SpO2 &lt;94%, RR&ge;24)<strong>.&nbsp;</strong><strong>Awake proning</strong> should be <strong>avoided</strong> in patients with <strong>hemodynamic instability</strong>.</p>\n</div>\n<div>Awake proning in moderate COVID disease is recommended for any patient with severe respiratory distress. It improves oxygenation by keeping the <strong>alveolar units open</strong>. Timely proning of patients with&nbsp;<strong>SpO2 &lt; 94%</strong> can help reduce mortality.</div>\n<div>&nbsp;</div>\n<div><strong>Steps for self-proning:</strong></div>\n<ul>\n<li>1 pillow below the neck</li>\n<li>1 or 2 pillows below the chest through upper thighs</li>\n<li>2 pillows below the shins</li>\n<li>Keep alternating between proning, laying on your right, sitting up, and laying on your left, in a lying position, ideally for not more than <strong>30 minutes</strong> in each position with an <strong>upper limit of 2 hours</strong>.</li>\n<li>One may prone <strong>up to 16 hours a day</strong>, in multiple cycles, if tolerable.</li>\n</ul>\n<div><strong>Avoid proning:</strong></div>\n<ul>\n<li>Hemodynamic instability</li>\n<li>For 1 hour after meals</li>\n<li>DVT, cardiac conditions</li>\n<li>Fractures of spine, femur, or pelvis</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3915",
      "difficulty": "medium"
    },
    {
      "text": "A 42-year-old COVID-19 positive man under home isolation develops breathing difficulty. SpO2 is 86%. He is administered oxygen via a face mask with a reservoir bag with a flow rate of 10 L/min. After a trial of one hour, his SpO2 is 88%. What is the next step?",
      "choices": [
        {
          "id": 1,
          "text": "Increase flow rate to 15 L/min"
        },
        {
          "id": 2,
          "text": "High-flow nasal cannula oxygen therapy"
        },
        {
          "id": 3,
          "text": "Endotracheal intubation"
        },
        {
          "id": 4,
          "text": "No specific intervention necessary"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This patient has <strong>persistent hypoxia</strong> after an adequate trial of standard oxygen therapy and should be started on <strong>high-flow nasal cannula oxygen therapy.&nbsp;</strong></p>\n<p>When respiratory distress and/or hypoxemia of the patient cannot be alleviated after receiving standard oxygen therapy, high&ndash;flow nasal cannula oxygen therapy (HFNO), or non&ndash;invasive ventilation can be considered. Compared to standard oxygen therapy, HFNO reduces the need for intubation.&nbsp;</p>\n<p>Patients on HFNO should be closely monitored, and endotracheal intubation should be done if the patient acutely deteriorates or does not improve after a short trial (about 1 hr).</p>\n<p><strong>Contraindications to HFNO</strong> includes patients with:</p>\n<ul>\n<li>Hypercapnia (exacerbation of COPD)</li>\n<li>Hemodynamic instability</li>\n<li>Multi-organ failure</li>\n<li>Abnormal mental status&nbsp;</li>\n</ul>\n<p><strong>Note:</strong> If an high flow nasal cannula (HFNC) or simple nasal cannula is used to administer O2, an N95 mask should be applied over it.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3925",
      "difficulty": "medium"
    },
    {
      "text": "An 84-year-old man is being treated in the ICU for sepsis induced respiratory failure secondary to COVID-19. What is the maximum tidal volume setting permissible for his mechanical ventilation? (PBW-predicted body weight)",
      "choices": [
        {
          "id": 1,
          "text": "4 ml/kg PBW"
        },
        {
          "id": 2,
          "text": "6 ml/kg PBW"
        },
        {
          "id": 3,
          "text": "8 ml/kg PBW"
        },
        {
          "id": 4,
          "text": "10 ml/kg PBW"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>A maximum tidal volume of up to <strong>8 ml/kg PBW</strong> is allowed in a patient with<strong> ARDS</strong> who is being mechanically ventilated.</p>\n<p>In patients with ARDS, mechanical ventilation should be implemented using <strong>lower tidal volumes</strong> (4&ndash;8 ml/kg PBW) and <strong>lower inspiratory pressures</strong> (plateau pressure &lt;30 cmH2O).</p>\n<p>In patients with <strong>moderate or severe ARDS</strong>, a&nbsp;<strong>higher PEEP</strong> is suggested. PEEP titration requires consideration of benefits (improving alveolar recruitment) vs. risks (end-inspiratory over distension leading to lung injury).</p>\n<p>Lung protective ventilation strategy by ARDS net protocol recommendations:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Parameters</strong></td>\n<td><strong>Values</strong></td>\n</tr>\n<tr>\n<td>Tidal volume&nbsp;</td>\n<td>6ml/kg</td>\n</tr>\n<tr>\n<td>RR&nbsp;</td>\n<td>15-35/min</td>\n</tr>\n<tr>\n<td>PEEP&nbsp;</td>\n<td>5-15cm H2O</td>\n</tr>\n<tr>\n<td>Target plateau pressure</td>\n<td>&lt; 30cm H2O</td>\n</tr>\n<tr>\n<td>Target SpO2</td>\n<td>88-95%</td>\n</tr>\n<tr>\n<td>Target PaO2&nbsp;</td>\n<td>55-80mmHg</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6831",
      "difficulty": "hard"
    },
    {
      "text": "An elderly diabetic man with COVID-19 is desaturating on non-invasive ventilation. You intubate him and place him on a mechanical ventilator. He improves briefly but the SpO2 suddenly drops. You suspect a tubal block and perform closed suctioning. Despite this, he goes into cardiac arrest and you start CPR. You would not expect aerosol generation in:",
      "choices": [
        {
          "id": 1,
          "text": "Non-invasive ventilation"
        },
        {
          "id": 2,
          "text": "Manual ventilation"
        },
        {
          "id": 3,
          "text": "Closed suctioning"
        },
        {
          "id": 4,
          "text": "CPR"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Open suctioning</strong> of the respiratory tract is associated with significant amounts of <strong>aerosol</strong> generation and not closed suctioning.</p>\n<p><strong>Commonly performed aerosol-generating procedures are:</strong></p>\n<ul>\n<li>Open suctioning of the respiratory tract</li>\n<li>Bronchoscopy</li>\n<li>Cardiopulmonary resuscitation (CPR)</li>\n<li>Non-invasive ventilation (e.g., BiPAP, CPAP)</li>\n<li>Endotracheal intubation and extubation</li>\n<li>Manual ventilation&nbsp;</li>\n</ul>\n<p>It is recommended that healthcare providers should be protected with <strong>PPE</strong> while performing these procedures. It must be performed in an adequately ventilated single room with a minimum of <strong>12 air changes/hour</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6816",
      "difficulty": "medium"
    },
    {
      "text": "A 67-year-old patient with end-stage renal disease is tested positive for COVID-19. Which anticoagulation agent would you recommended for him?",
      "choices": [
        {
          "id": 1,
          "text": "Unfractionated heparin"
        },
        {
          "id": 2,
          "text": "LMWH"
        },
        {
          "id": 3,
          "text": "Warfarin"
        },
        {
          "id": 4,
          "text": "Dabigatran"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of<strong>&nbsp;COVID-19</strong> in a patient with&nbsp;<strong>end-stage renal disease</strong>.&nbsp;<strong>Unfractionated heparin</strong> is recommended for use in such patients.</p>\n<p><strong>Prophylactic anticoagulation</strong> is used in the management of <strong>moderate and severe COVID</strong> cases. A prophylactic dose of low molecular weight heparin or unfractionated heparin is used to prevent thromboembolism. In a COVID patient with end-stage renal disease, unfractionated heparin is the preferred agent.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6846",
      "difficulty": "hard"
    },
    {
      "text": "Which case scenarios along with the drugs prescribed are inappropriate?<div class='question-desc-html'><ol>\n<li><span data-preserver-spaces=\"true\">A man on anti-retroviral therapy with severe COVID pneumonia- Tocilizumab</span></li>\n<li><span data-preserver-spaces=\"true\">A non-hospitalized middle-aged diabetic man with mild COVID pneumonia- Bamlanivimab</span></li>\n<li><span data-preserver-spaces=\"true\">A mother on post-partum day 3 with moderate COVID pneumonia maintaining with NIPPV- Remedisivir</span></li>\n<li><span data-preserver-spaces=\"true\">A woman with COVID-19 disease- Convalescent plasma therapy</span></li>\n<li><span data-preserver-spaces=\"true\">A woman with moderate COVID pneumonia on supplemental oxygen- Dexamethasone</span></li>\n</ol>\n<p><span data-preserver-spaces=\"true\">&nbsp;</span></p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3, 4, 5"
        },
        {
          "id": 2,
          "text": "1, 2, 3, and 4 only"
        },
        {
          "id": 3,
          "text": "3, 4 and 5"
        },
        {
          "id": 4,
          "text": "1 and 2 only"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span data-preserver-spaces=\"true\">The correct answer is <strong>1, 2, 3, and 4.</strong></span></p>\n<ol>\n<li><span data-preserver-spaces=\"true\">Tocilizumab is <strong>contraindicated</strong> in<strong> HIV-positive</strong> patients and those with active bacterial or fungal infection.</span></li>\n<li><span data-preserver-spaces=\"true\">Bamlanivimab is <strong>not</strong>&nbsp;</span><span data-preserver-spaces=\"true\">authorized for patients with&nbsp;<strong>mild&nbsp;</strong></span><span data-preserver-spaces=\"true\">COVID-19 pneumonia who are not at&nbsp;a high risk for <strong>hospitalization</strong>.</span></li>\n<li><span data-preserver-spaces=\"true\">Remedisivir is <strong>contraindicated </strong>in<strong> postnatal</strong> lactating women.</span></li>\n<li><span data-preserver-spaces=\"true\">Convalescent plasma therapy is&nbsp;<strong>no longer recommended</strong>&nbsp;in the management of COVID patients.</span></li>\n</ol>\n<p><strong><span data-preserver-spaces=\"true\">Tocilizumab</span></strong><span data-preserver-spaces=\"true\">&nbsp;acts by <strong>IL-6 inhibition</strong>. It may be considered in moderate-severe COVID patients with progressively increasing oxygen requirements and mechanically ventilated patients not improving despite the use of steroids. Patients should be carefully monitored for secondary infections and neutropenia after treatment with tocilizumab. It is contraindicated in:</span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">HIV&nbsp;</span></li>\n<li><span data-preserver-spaces=\"true\">Active infections (systemic bacterial/fungal)</span></li>\n<li><span data-preserver-spaces=\"true\">Tuberculosis</span></li>\n<li><span data-preserver-spaces=\"true\">Active hepatitis</span></li>\n<li><span data-preserver-spaces=\"true\">Absolute neutrophil count &lt; 2000/mm3</span></li>\n<li><span data-preserver-spaces=\"true\">Platelet count &lt; 1,00,000/mm3</span></li>\n</ul>\n<p><strong><span data-preserver-spaces=\"true\">Bamlanivimab</span></strong><span data-preserver-spaces=\"true\">&nbsp;is a monoclonal antibody directed against the&nbsp;</span><strong><span data-preserver-spaces=\"true\">spike protein</span></strong><span data-preserver-spaces=\"true\">&nbsp;of SARS-CoV-2. The FDA has issued an <strong>emergency use authorization</strong> for bamlanivimab for the treatment of adult and pediatric mild to moderate COVID patients (12 years of age and older weighing at least 40 kilograms) who are at high risk for progressing to severe COVID-19 and/or hospitalization.&nbsp;</span><span data-preserver-spaces=\"true\">Possible side effects include anaphylaxis and infusion-related reactions, nausea, diarrhea, dizziness, headache, itching, and vomiting. There is&nbsp;</span><strong><span data-preserver-spaces=\"true\">no specific contraindication</span></strong><span data-preserver-spaces=\"true\">&nbsp;for this drug.&nbsp;</span></p>\n<p><strong><span data-preserver-spaces=\"true\">Remdesivir&nbsp;</span></strong><span data-preserver-spaces=\"true\">is an</span><span data-preserver-spaces=\"true\">&nbsp;antiviral drug that works by <strong>inhibiting RNA-dependent RNA polymerase</strong>. It may be considered in moderate and severe hospitalized COVID patients requiring supplemental oxygen/oxygen delivery through a high flow device/ noninvasive ventilation/ invasive mechanical ventilation/ ECMO.&nbsp;</span><span data-preserver-spaces=\"true\">It is contraindicated in:&nbsp;</span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">AST/ALT &gt; 5 times upper limit of normal</span></li>\n<li><span data-preserver-spaces=\"true\">Severe renal impairment (i.e., eGFR &lt; 30ml/min/m2 or need for hemodialysis)&nbsp;</span></li>\n<li><span data-preserver-spaces=\"true\">Pregnancy or lactating females&nbsp;</span></li>\n<li><span data-preserver-spaces=\"true\">Children &lt;12 years of age</span></li>\n</ul>\n<p><strong>Convalescent plasma therapy</strong> is no longer recommended in the management of COVID patients, as per the revised guidelines.</p>\n<p><strong><span data-preserver-spaces=\"true\">Dexamethasone</span></strong><span data-preserver-spaces=\"true\">&nbsp;is generally given to all patients of moderate and severe COVID-19. Patients with severe COVID-19 can develop a</span><strong><span data-preserver-spaces=\"true\">&nbsp;systemic inflammatory response</span></strong><span data-preserver-spaces=\"true\">&nbsp;that can lead to lung injury and multisystem organ dysfunction. </span></p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8469",
      "difficulty": "medium"
    },
    {
      "text": "A  G2P1 woman presents to the clinic at 36 weeks of gestation. Her husband was COVID positive and now she has also been tested positive. What is true regarding her management?",
      "choices": [
        {
          "id": 1,
          "text": "C-section is the preferred mode of delivery"
        },
        {
          "id": 2,
          "text": "Awake proning is not recommended"
        },
        {
          "id": 3,
          "text": "CT scan is absolutely contraindicated"
        },
        {
          "id": 4,
          "text": "Aim to keep oxygen saturation more than 94% during labour"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of&nbsp;<strong>COVID-19</strong> disease in a <strong>pregnant</strong> patient. The management should include an aim to keep <strong>oxygen saturation above 94%</strong> during labour in this patient. In such cases, maternal observations and assessment during labour should be continued as per standard practice, with the addition of <strong>hourly oxygen saturation.&nbsp;</strong></p>\n<p>Option A:&nbsp;There is currently <strong>no evidence to favour one mode of birth </strong>over another. Mode of birth should not be influenced by the presence of COVID-19, unless the woman&rsquo;s respiratory condition demands urgent intervention for birth.</p>\n<p>Option B:&nbsp;<strong>Awake proning</strong> is recommended.&nbsp;Although evidence is limited, there are reports that this is feasible with <strong>appropriate padding</strong> up to at least 28 weeks of gestation.</p>\n<p>Option C:&nbsp;<strong>CT</strong> scan is <strong>relatively contraindicated</strong>. Pregnant women with <strong>abdominal shielding</strong> should not be excluded from chest CT if clinically recommended.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3923",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is a criterion for discharge in a patient with mild COVID-19 infection?",
      "choices": [
        {
          "id": 1,
          "text": "Discharge after 10 days from testing positive & no fever for 3 days"
        },
        {
          "id": 2,
          "text": "Discharge after 7 days from testing positive & no fever for 3 days"
        },
        {
          "id": 3,
          "text": "Discharge if SpO2>98% on room air for 3 consecutive days"
        },
        {
          "id": 4,
          "text": "Discharge if repeat RT-PCR testing is negative"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>COVID-19 cases that are <strong>mild/very mild/presymptomatic</strong> can be discharged from home isolation after <strong>7</strong><strong>&nbsp;days </strong>of <strong>testing positive</strong><strong>&nbsp;</strong>and<strong> no fever </strong>for<strong> 3 successive days.&nbsp;</strong>There is no need for testing after the end of home isolation.&nbsp;</p>\n<p>Criteria to diagnose asymptomatic COVID-19: Laboratory confirmed case with no symptoms with a saturation of more than 93% in room air.&nbsp;</p>\n<p>Criteria to diagnose mild COVID-19:&nbsp;Laboratory confirmed case with upper respiratory tract symptoms with/without fever, without shortness of breath, and saturation of more than 93% in room air.&nbsp;</p>\n<p>Patients are advised to isolate from other family members and monitor themselves at home, under proper medical guidance.&nbsp;Patients &gt;60 years with co-morbidities, and immunocompromised patients are allowed to isolate only after receiving clearance from the designated medical officer.&nbsp;</p>\n<p>Immediate medical attention is required if the patient experiences the following:&nbsp;</p>\n<ul>\n<li>A 100 &ordm;F fever persists for &gt;3 days and does not resolve on medication.</li>\n<li>Difficulty in breathing&nbsp;</li>\n<li>Oxygen saturation&nbsp;&le;93% (at least 3 readings within 1 hour)</li>\n<li>Respiratory rate&nbsp;&gt;24/min</li>\n<li>Persistent chest pain or pressure</li>\n<li>Mental confusion&nbsp;</li>\n<li>Severe fatigue or myalgia&nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6833",
      "difficulty": "medium"
    },
    {
      "text": "A 33-year-old delivery boy tested COVID-19 positive. He started experiencing worsening breathlessness and cough and  rushed to the hospital when his pulse oximeter reading was 87%. Following treatment, he showed signs of improvement. What is correct before discharging him?",
      "choices": [
        {
          "id": 1,
          "text": "Discharge after 7 days from symptom onset & no fever for 3 days"
        },
        {
          "id": 2,
          "text": "Discharge if repeat RT-PCR testing is negative after recovery"
        },
        {
          "id": 3,
          "text": "Discharge if SpO2>98% on room air for 3 consecutive days"
        },
        {
          "id": 4,
          "text": "Discharge at the discretion of the treating medical officer"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of&nbsp;<strong>severe COVID-19</strong> disease.&nbsp;Severe cases of COVID-19 (and <strong>immunocompromised</strong> patients) are discharged based on their clinical recovery at the discretion of the treating medical officer.&nbsp;</p>\n<p>Note: <strong>Mild</strong> and <strong>moderate</strong> cases do not need an RT-PCR test before discharge. But, at the time of discharge, they are advised to&nbsp;<strong>self-monitor </strong>and&nbsp;<strong>continue wearing masks</strong>&nbsp;for a duration of 7 days.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6834",
      "difficulty": "hard"
    },
    {
      "text": "A 10-year-old boy with COVID-19 presents with sore throat, rhinorrhea and cough. He does not have fast breathing. What is recommended for this child?<div class='question-desc-html'><ol>\n<li><strong>Home isolation</strong></li>\n<li><strong>Hospital admission</strong></li>\n<li><strong>Awake proning</strong></li>\n<li><strong>Antibiotics</strong></li>\n<li><strong>Low dose steroids</strong></li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "2 and 5"
        },
        {
          "id": 2,
          "text": "3 only"
        },
        {
          "id": 3,
          "text": "2 and 4"
        },
        {
          "id": 4,
          "text": "1 only"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The presence of sore throat, rhinorrhea, cough with no fast breathing are suggestive of <strong>mild</strong> <strong>COVID-19 </strong>disease. Hence, <strong>home isolation</strong> along with supportive care is recommended in this child.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f392507b3b8641adb039521bd36fda16x1280x4635.JPEG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p><strong>Remdesivir</strong> (an emergency use authorization drug) is <strong>not recommended </strong>in<strong> children</strong>. There is lack of sufficient evidence on safety and efficacy with respect to remdesivir in children below 18 years of age.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME7870",
      "difficulty": "medium"
    },
    {
      "text": "FDA has recently sanctioned emergency use authorization to the first oral antiviral drug combination for the treatment of COVID-19. This drug combination contains:",
      "choices": [
        {
          "id": 1,
          "text": "Nirmatrelvir and Ritonavir"
        },
        {
          "id": 2,
          "text": "Molnupiravir and Ritonavir"
        },
        {
          "id": 3,
          "text": "Nirmatrelvir and Indinavir"
        },
        {
          "id": 4,
          "text": "Molnupiravir and Indinavir"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>FDA recently sanctioned emergency use authorization to a combination of <strong>nirmatrelvir and ritonavir</strong> tablets (Paxlovid) for the treatment of mild-to-moderate COVID-19. It is the <strong>first oral antiviral</strong> for the treatment of <strong>COVID-19.</strong></p>\n<p><strong>Nirmatrelvir</strong> is a <strong>peptidomimetic</strong> inhibitor of the <strong>SARS-CoV-2 main protease</strong> (Mpro). Inhibition of this enzyme makes the virus incapable of processing polyprotein precursors and thus prevents viral replication.</p>\n<p><strong>Ritonavir</strong> is an HIV-1 <strong>protease inhibitor.</strong> It inhibits the CYP3A-mediated metabolism of nirmatrelvir which results in increased plasma concentrations of nirmatrelvir. It is <strong>not active</strong> against SARS-CoV-2 Mpro.</p>\n<p>Patients who tested positive with direct SARS-CoV-2 test can be administered this drug combination, provided they are:</p>\n<ul>\n<li aria-level=\"1\">12 years of age and older</li>\n<li aria-level=\"1\">Weighing at least 40 kgs</li>\n<li aria-level=\"1\">At high risk for progression to severe COVID-19.</li>\n</ul>\n<p>Contraindications include hypersensitivity reactions to the active ingredients or any other components, co-administration with drugs highly dependent on CYP3A for clearance, co-administration with potent CYP3A inducers. Adverse reactions include dysgeusia, diarrhea, hypertension, and myalgia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2940",
      "difficulty": "medium"
    }
  ]
}